BMS-986353 is an investigational CD19-targeted CAR T-cell product. The CD19-specific CAR consists of a single-chain variable fragment (scFv) binding domain derived from a CD19-specific monoclonal antibody (mAb; FMC63), an IgG-derived hinge region, a CD28 transmembrane domain, and the CD137 (41BB) and CD3? chain signaling domains. The third-generation SIN lentiviral vector, which encodes the CAR domains described above, also encodes a truncated human epidermal growth factor receptor (EGFRt) that is expressed separately from the CD19 CAR on the T cell surface
Multiple Sclerosis
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 65/ 100
Competitive context
182 Active assets in the Multiple Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cladribine University Hospital, Strasbourg, France | Phase 4 | BBB |
Nabiximols Jazz Pharmaceuticals | Phase 4 | BBB |
Teriflunomide Sanofi | Phase 4 | BBB |
Fampridine MGH Institute of Health Professions | Phase 4 | BBB |
Ocrevus Polpharma Biologics International AG | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
BMS-986353 is an investigational CD19-targeted CAR T-cell product. The CD19-specific CAR consists of a single-chain variable fragment (scFv) binding domain derived from a CD19-specific monoclonal antibody (mAb; FMC63), an IgG-derived hinge region, a CD28 transmembrane domain, and the CD137 (41BB) and CD3? chain signaling domains. The third-generation SIN lentiviral vector, which encodes the CAR domains described above, also encodes a truncated human epidermal growth factor receptor (EGFRt) that is expressed separately from the CD19 CAR on the T cell surface is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →